PureTech entity Celea raises $180 million to move lung disease drug into late stage trial

July 2 (Reuters) - Celea Therapeutics, linked to PureTech Health, on Thursday completed a $180 million financing round for a late-stage trial of its lung disease drug, deupirfenidone, in patients with ...

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis ...

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to IPF ...

PureTech spinout lands $180M from investors including RA Capital, Leaps by Bayer

Boston biotech Celea Therapeutics raised $180 million from RA Capital, Leaps by Bayer and others to fund a Phase 3 trial of ...
Nasdaq

PureTech Health Cash Runway Extended

PureTech Health(NASDAQ:PRTC) reported its second quarter 2025 earnings on Aug. 28, 2025, highlighting a cash balance of just under $320 million at the end of the first half of 2025, a reduction in ...
Business Wire

PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds. PureTech retains ...
The Business Journals

PureTech’s founding CEO takes new role as head of Boston biotech

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Daphne Zohar, who founded Boston ...